scholarly journals Expression of platelet-derived growth factor B is upregulated in patients with thoracic aortic dissection

2018 ◽  
Vol 68 (6) ◽  
pp. 3S-13S ◽  
Author(s):  
Weixin Meng ◽  
Shangdian Liu ◽  
Dandan Li ◽  
Zonghong Liu ◽  
Hui Yang ◽  
...  
Keyword(s):  
Growth Factor ◽  
Aortic Dissection ◽  
Platelet Derived Growth Factor ◽  
Factor B ◽  
Thoracic Aortic Dissection

scholarly journals Assignment of intrachain disulfide bonds in platelet-derived growth factor B-chain

1993 ◽  
Vol 268 (18) ◽  
pp. 13372-13377
Author(s):  
A. Ostman ◽  
M. Andersson ◽  
G. Bäckström ◽  
C.H. Heldin
Keyword(s):  
Growth Factor ◽  
Disulfide Bonds ◽  
Platelet Derived Growth Factor ◽  
Factor B

Molecular Targeting of Platelet-Derived Growth Factor B by Imatinib Mesylate in a Patient With Metastatic Dermatofibrosarcoma Protuberans

2002 ◽  
Vol 20 (17) ◽  
pp. 3586-3591 ◽  
Author(s):  
Brian P. Rubin ◽  
Scott M. Schuetze ◽  
Janet F. Eary ◽  
Thomas H. Norwood ◽  
Sohail Mirza ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Imatinib Mesylate ◽  
Kinase Inhibitor ◽  
Dermatofibrosarcoma Protuberans ◽  
Response To Therapy ◽  
Platelet Derived Growth Factor ◽  
Response To Treatment ◽  
Resected Specimen ◽  
Factor B

PURPOSE: Dermatofibrosarcoma protuberans is caused by activation of the platelet-derived growth factor B (PDGFB) receptor, a transmembrane tyrosine kinase. We investigated the response of dermatofibrosarcoma protuberans to the tyrosine kinase inhibitor imatinib mesylate. PATIENTS AND METHODS: A patient with unresectable, metastatic dermatofibrosarcoma protuberans received imatinib mesylate (400 mg bid). Response to therapy was assessed by [18F]fluorodeoxyglucose (FDG) positron emission tomography, magnetic resonance imaging, and histopathologic and immunohistochemical evaluation. RESULTS: The patient was treated for 4 months with imatinib mesylate. The hypermetabolic uptake of FDG fell to background levels within 2 weeks of treatment, and the tumor volume shrank by over 75% during the 4 months of therapy, allowing for resection of the mass. There was no residual viable tumor in the resected specimen, indicating a complete histologic response to treatment with imatinib mesylate. CONCLUSION: Imatinib mesylate is highly active in dermatofibrosarcoma protuberans. The dramatic response seen in this patient demonstrates that inhibition of PDGFB receptor tyrosine kinase activity can significantly impact viability of at least one type of solid tumor.

scholarly journals Adenoviral-Mediated Overexpression of Platelet-Derived Growth Factor-B Corrects Ischemic Impaired Wound Healing

1999 ◽  
Vol 113 (3) ◽  
pp. 375-383 ◽  
Author(s):  
Kenneth W. Liechty ◽  
Mark Nesbit ◽  
Meenhard Herlyn ◽  
Antoneta Radu ◽  
N. Scott Adzick ◽  
...  
Keyword(s):  
Wound Healing ◽  
Growth Factor ◽  
Platelet Derived Growth Factor ◽  
Impaired Wound Healing ◽  
Factor B
Sign in / Sign up

Export Citation Format

Share Document